Patients and method: descriptive study on 97 patient diagnosed with adenocarcinoma non small cell lung cancer stage IV, age > 60 years, EGFR mutations (exon 19 deletion mutation or L858R) at Vietnam National Cancer Hospital, from March 2017 to March 2022, received first line treatment with the first molecular targeted agent (Gefitinib or Erlotinib) Results: Overall response rate was 66%, disease control rate was 85.6%.